SCHEMBL801240

SCHEMBL801240

O=CNc1ccc([N+](=O)[O-])c(N2CC2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
MAPT P10636 6/20 0.52
MAPK1 P28482 4/20 0.52
POLB P06746 4/20 0.52
TDP1 Q9NUW8 2/20 0.52
CYP1A2 P05177 3/20 0.42
CYP2C9 P11712 3/20 0.42
CYP2C19 P33261 2/20 0.42
SERPINE1 P05121 1/20 0.41
GRM5 P41594 2/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
HTT P42858 1/20 0.38
HPGD P15428 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
TNNI3 P19429 1/20 0.36
TNNT2 P45379 1/20 0.36
TNNC1 P63316 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801080 0.75 TDP1 (0.38) ALDH1A1MAPTMAPK1TDP1
SCHEMBL11008789 0.72 MAPT (0.45) ALDH1A1MAPTMAPK1POLBTDP1
SCHEMBL9437329 0.71 MAPT (0.44) ALDH1A1MAPTMAPK1POLBTDP1
SCHEMBL21627103 0.71 ALDH1A1 (0.69) ALDH1A1MAPTMAPK1POLBTDP1
SCHEMBL782065 0.70 MAPT (0.55) ALDH1A1MAPTMAPK1POLBTDP1
SCHEMBL801083 0.70 ALDH1A1 (0.52) ALDH1A1MAPTMAPK1POLBTDP1
SCHEMBL2416386 0.69 ALDH1A1 (1.00) ALDH1A1MAPTMAPK1POLBTDP1
SCHEMBL1172567 0.68 SERPINE1 (0.55) ALDH1A1MAPTMAPK1POLBTDP1
SCHEMBL101570 0.68 ALDH1A1 (0.69) ALDH1A1MAPTMAPK1POLBTDP1
SCHEMBL11654178 0.68 ALDH1A1 (0.69) ALDH1A1MAPTMAPK1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940770-B2 Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof BEIJING YILING BIOENGINEERING CO., LTD. (CN) 2015-01-27 US disclosed
US-20140073796-A1 NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF BEIJING YILING BIOENGINEERING CO., LTD (CN) 2014-03-13 US disclosed
US-20120071515-A1 NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF BEIJING YILING BIOENGINEERING CO., LTD (CN) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071515-A1 NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF ENPP1, DPYD, NME2 ALDH1A1 1271/4885MAPT 3373/4885MAPK1 3685/4885
US-20140073796-A1 NITROPYRIDINYL ETHYLENEIMINE COMPOUND, THE PHARMACEUTICAL COMPOSITION CONTAINING IT, THE PREPARATION METHOD AND USE THEREOF ENPP1, DPYD, NME2 ALDH1A1 1271/4885MAPT 3373/4885MAPK1 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.